metastatic pancreatic endocrine carcinoma (DBCOND0022757)

Identifiers

Synonyms

Pancreatic Carcinoma Metastatic / Metastatic Pancreatic Carcinoma / Pancreatic carcinoma stage IV / Metastasis from pancreatic endocrine carcinoma (disorder)

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Capecitabine	A nucleoside metabolic inhibitor indicated to treat different gastrointestinal, including pancreatic cancer, and breast cancer.	Thymidylate synthasetarget Thymidine phosphorylaseenzyme Cytidine deaminaseenzyme Liver carboxylesterase 1enzyme Cytochrome P450 2C9enzyme DNAtarget RNAtarget Albumincarrier Uridine phosphorylase 1enzyme Uridine phosphorylase 2enzyme Thymidylate synthasetarget

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT03152487	Trial Comparing EUS-guided Radiofrequency Ablation vs. EUS-guided Celiac Plexus Neurolysis	No drug interventions	treatment	Not Available	completed
NCT05642962	Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)	Pancrelipase Pancrelipase amylase Pancrelipase lipase Pancrelipase protease	treatment	1 / 2	recruiting
NCT04659603	Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors	Gemcitabine Tusamitamab ravtansine	treatment	2	active_not_recruiting
NCT01547260	Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer	Gemcitabine Lenalidomide	treatment	1 / 2	completed
NCT02391662	Nab-paclitaxel and Gemcitabine, in Elderly Patients Untreated Metastatic Pancreatic Adenocarcinoma	Gemcitabine Paclitaxel	treatment	2	completed
NCT04550494	Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations	Talazoparib	treatment	2	recruiting
NCT05053971	Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas	Entinostat	treatment	1 / 2	recruiting
NCT00480584	A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer	Capecitabine Erlotinib Gemcitabine	treatment	1	completed
NCT05038254	Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events	No drug interventions	health_services_research	Not Available	recruiting
NCT00137761	Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer	Docetaxel Gefitinib	treatment	2	completed
NCT04858009	Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis	Albumin human Chloride ion Cisplatin Paclitaxel Platinum	treatment	2	recruiting
NCT03033225	Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study	Verteporfin	treatment	2	completed
NCT03825289	Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer	Hydroxychloroquine Trametinib	treatment	1	recruiting
NCT04390243	Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation	Binimetinib Encorafenib	treatment	2	terminated
NCT05733000	CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors	Devimistat Fluorouracil Gemcitabine Hydroxychloroquine Lipoic acid	treatment	2	recruiting
NCT00843830	A Pilot Study Assessing Intra-Metastasis Administration of Autologous KLH-pulsed Dendritic Cells With Tumoral Radiation Therapy in Patients With Metastatic Pancreatic Carcinoma	No drug interventions	treatment	1	terminated
NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	Dostarlimab Niraparib	treatment	1	recruiting
NCT03818165	Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases	No drug interventions	treatment	1	terminated
NCT02595931	M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	Berzosertib Camptothecin Irinotecan	treatment	1	active_not_recruiting
NCT05759923	First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours	No drug interventions	treatment	1	recruiting